New data on ruxolitinib cream (Opzelura™) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking oral presentation WILMINGTON, Del. –(BUSINESS WIRE)–Mar.

Original Source

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219